Research programme: immunotherapeutics - Harbour BioMed/Vir Biotechnology
Latest Information Update: 28 Sep 2024
At a glance
- Originator Harbour BioMed; Vir Biotechnology
- Class Anti-infectives; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Infections
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for research development in Cancer in China (Parenteral)
- 28 Sep 2024 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 28 Sep 2024 No recent reports of development identified for research development in Infections in China (Parenteral)